Therapeutic Neuromodulation Systems, LLC, a US-based sales & marketing organization, announces the US Food and Drug Administration (FDA) has granted 510(k) clearance for the Morph Device, a percutaneous nerve field stimulatory system (PNFS) with an indication for use as an aid in the reduction of withdrawal symptoms associated with detoxification. As a purpose-driven company and innovator in wearable device technology, our goal is to increase treatment participation by removing the FEAR and PAIN associated with opiate withdrawal. Bryant George, MD: “The Morph Device is effective for treating the acute pain occurring from opioid withdrawal. It is not a cure for addiction. Evidence of its method of action can be found in addiction medicine textbooks. The electrical stimulation enhances the release of neuropeptides, primarily beta-endorphin and enkephalins in the central nervous system. These neuropeptides then bind to the vacant mu and delta receptors thereby alleviating the symptoms of physical withdrawal. The Morph is used to detoxify opioid dependent without the patient experiencing the discomfort of withdrawal symptoms. In my practice, patients are then subjected to cognitive behavioral therapy and extended-release naltrexone injections or implants after detoxification. The successful treatment of opioid-dependent patients is no doubt challenging and requires addressing multiple issues. For those patients that are motivated to be opioid-free, their most significant initial obstacle is the anxiety of the intense physical discomfort of detoxification. People that are good Candidates are those that are using only because they are afraid of withdrawal sickness. "
